MDGL compared with ARGX: revenue, margins and what each company keeps, and the suppliers and customers both name

MDGLMadrigal Pharmaceuticals, Inc.

Mkt capRevenueRevenue

ARGXArgenx SE

Mkt capRevenueRevenue

Compare

MDGLMadrigal Pharmaceuticals, Inc.

ARGXArgenx SE

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

MDGL, solidARGX, dashed

Supply-chain overlap

Revenue flow

MDGL: latest quarter is a loss; flow not drawable. ARGX: latest quarter not drawable.Method ›

MDGLMadrigal Pharmaceuticals, Inc.

430.17▼−0.35%· post 433.06

Mkt cap$9.9BRevenue$364MQ2 FY26Revenue$958MFY25

ARGXArgenx SE

893.85▼−0.45%· post 895.00

ClosedOct 30 '26

Mkt cap$55.3BRevenue—Revenue—

Compare

ClosedOct 30 '26

MDGLMadrigal Pharmaceuticals, Inc.

ARGXArgenx SE

430.17▼−0.35%post 433.06

Price

893.85▼−0.45%post 895.00

$9.9B

Mkt cap

$55.3B

Q2 FY26$364M

Revenue

—

FY25$958M

Revenue

—

MDGL430.17▼−0.35%vsARGX893.85▼−0.45%ClosedOct 30 '26

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only MDGL 8

PFEPfizersupplier

—Gregory Pharmaceutical Holdings, Inc. (d/b/a UPM Pharmaceuticals)unlistedsupplier

—Rocheunlistedsupplier

—Cowenunlistedsupplier

4 more · MDGL chain ›

Shared 0

No shared counterparties.

Only ARGX 3

ABBVAbbViecustomer

HALOHalozyme Therapeuticssupplier

—AgomAb Therapeuticsunlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR